Results 61 to 70 of about 32,201 (250)

Long COVID in People With Multiple Sclerosis and Related Disorders: A Multicenter Cross‐Sectional Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Managing long COVID in people with multiple sclerosis and related disorders (pwMSRD) is complex due to overlapping symptoms. To address evidence gaps, we evaluated long COVID susceptibility in pwMSRD versus controls and its associations with multi‐domain function and disability.
Chen Hu, Jiyeon Son, Lindsay McAlpine, Elizabeth L. S. Walker, Megan Dahl, Emily Song, Sugeidy Ferreira Brito, Katelyn Kavak, Kaho Onomichi, Amit Bar‐Or, Christopher Perrone, Claire S. Riley, Bianca Weinstock‐Guttman, Philip L. De Jager, Erin E. Longbrake, Zongqi Xia   +15 more
wiley   +1 more source

Features of the diagnosis and treatment of patients with AQP-4-positive neuromyelitis optica and MOG antibody disease

Русский журнал детской неврологии, 2021
Background. As the amount of knowledge about multiple sclerosis increases, there is an interest in other forms of demyelinating diseases, among which neuromyelitis optica spectrum disorder and MOG (myelin oligodendrocyte glycoprotein) antibody disease ...
V. E. Avdeeva, A. S. Kotov
doaj   +1 more source

Cognitive Impairment in Neuromyelitis Optica Spectrum Disorders: A Review of Clinical and Neuroradiological Features [PDF]

, 2019
Neuromyelitis optica spectrum disorders (NMOSD) are mostly relapsing autoimmune inflammatory disorders of the central nervous system (CNS) with optic neuritis, myelitis, and brainstem syndromes as clinical hallmarks.
Brandt, Alexander U., Oertel, Frederike Cosima, Paul, Friedemann, Schließeit, Jana   +3 more
core   +1 more source

Hydrocephalus in neuromyelitis optica [PDF]

Neurology, 2014
A majority of patients with neuromyelitis optica (NMO) spectrum disorders (NMOSD) have MRI brain abnormalities, some of which are “NMO-typical” with localization in aquaporin 4 (AQP4)–rich circumventricular and periaqueductal regions.1 Although uncommon in adult patients, symptomatic brain involvement occurs in approximately 50% of NMO–immunoglobulin G
Corey A. McGraw, Stacey L. Clardy, Orna O'Toole, Claudia F. Lucchinetti, Sean J. Pittock, Yong Guo, Karl N. Krecke, Stephen Krieger, Clara D. Boyd, Brian G. Weinshenker, Vanda A. Lennon   +10 more
openaire   +3 more sources

Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Soluble interleukin‐2 receptor (sIL‐2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) pathogenesis. However, sIL‐2R has so far not been evaluated in these conditions.
Philipp Klyscz, Carolin Otto, Klemens Ruprecht, Susanna Asseyer, Hannes Ole Tiedt, Christian Meisel, Judith Bellmann‐Strobl, Friedemann Paul, Patrick Schindler   +8 more
wiley   +1 more source

Growth Differentiation Factor 15 Elevation in the Central Nervous System Is Associated With Failure to Thrive in Alexander Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Alexander disease (AxD) is a severe neurodegenerative disorder caused by gain‐of‐function mutations in the gene for GFAP, which lead to protein aggregation and a primary astrocytopathy. Symptoms vary, but failure to thrive (FTT) and frequent emesis are common and cause significant morbidity. Here we investigate GDF15, a member of the
Tracy L. Hagemann, Michelle M. Sonsalla, Cora Luzinski, Fernando Zacahua, David A. Harris, Dudley W. Lamming, Albee Messing   +6 more
wiley   +1 more source

Higher frequency of brain abnormalities in neuromyelitis optica spectrum disorder patients without primary Sjögren′s syndrome

Neural Regeneration Research, 2016
Neuromyelitis optica spectrum disorder often co-exists with primary Sjögren′s syndrome. We compared the clinical features of 16 neuromyelitis optica spectrum disorder patients with (n = 6) or without primary Sjögren′s syndrome (n = 10).
Li-na Gu, Min Zhang, Hui Zhu, Jing-yao Liu   +3 more
doaj   +1 more source

Neuromyelitis optica spectrum disorder (NMOSD) – diagnosis, epidemiology, clinical course, treatment

Aktualności Neurologiczne, 2019
Devic’s disease (neuromyelitis optica, NMO) was first described under this name in 1894, and it was originally thought of as a variant of multiple sclerosis.
Agnieszka Damiza-Detmer, Marta Milewska-Jędrzejczak, Małgorzata Pawełczyk, Izabela Damiza, Andrzej Głąbiński   +4 more
doaj   +1 more source

Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G. [PDF]

, 2014
Background Although optic neuritis (ON) is a defining feature of neuromyelitis optica (NMO), appropriate animal models of NMO ON are lacking. Most NMO patients are seropositive for immunoglobulin G autoantibodies (NMO-IgG) against the astrocyte water ...
Asavapanumas, N, Bennett, JL, Levin, MH, Papadopoulos, MC, Ratelade, J, Verkman, Alan, Verkman, AS   +6 more
core   +2 more sources

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate [PDF]

BMC Neurology, 2014
To review our experience using methotrexate as a single long-term immunosuppressant (IS) therapy in neuromyelitis optica/neuromyelitis optica spectrum disorders (NMO/NMOSD).We performed a retrospective chart review of all patients with a diagnosis of NMO/NMOSD, supported by a positive NMO-IgG testing, who were treated with methotrexate. A paired sample
Ramnath Santosh Ramanathan, Konark Malhotra, Thomas F. Scott   +2 more
openaire   +3 more sources